Milton M. Morris joined NeuSpera® Medical as its President and CEO in July of 2015. Prior to taking on this role, Milton was a consultant with NeuSpera® helping to formulate the company’s strategy, establish and drive its programs and launch its formal fundraising activity. During his time as a consultant, Milton became an investor in NeuSpera® and a Director on its Board.

Prior to consulting for NeuSpera®, Milton was the Sr. Vice President of Research & Development and Emerging Therapies at Cyberonics. Dr. Morris joined Cyberonics as Vice President, Research & Development in January 2009. During his tenure with Cyberonics, the R&D organization has seen significant growth, hiring top medical device talent with relevant skills in ASIC development, neurophysiology/epilepsy, algorithm development, signal processing, alternative powering, RF communication and development of class III active implantable medical devices. Dr. Morris joined Cyberonics from InnerPulse Corporation, a privately held cardiology-focused medical technology start-up company in the Research Triangle Park of North Carolina, where he served as Director, Program Management and Operations. Prior to InnerPulse, Dr. Morris was employed by Guidant Corporation and its successor, Boston Scientific Corporation. During his tenure, he held several positions, including Principal Research Scientist; Director, Research & Development; and Director, Marketing where he served as the Arrhythmia Franchise leader with responsibilities for both the implantable pacemaker and defibrillator businesses for the Cardiac Rhythm Management division of Boston Scientific.